- Home
- PTHL vs ADAG Comparison
PTHL vs ADAG Comparison
Compare PTHL & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PTHL
- ADAG
- Stock Information
- Founded
- PTHL 1998
- ADAG 2011
- Country
- PTHL China
- ADAG China
- Employees
- PTHL N/A
- ADAG N/A
- Industry
- PTHL
- ADAG Biotechnology: Pharmaceutical Preparations
- Sector
- PTHL
- ADAG Health Care
- Exchange
- PTHL Nasdaq
- ADAG Nasdaq
- Market Cap
- PTHL 85.4M
- ADAG 76.3M
- IPO Year
- PTHL 2024
- ADAG 2021
- Fundamental
- Price
- PTHL $12.23
- ADAG $1.94
- Analyst Decision
- PTHL
- ADAG Strong Buy
- Analyst Count
- PTHL 0
- ADAG 1
- Target Price
- PTHL N/A
- ADAG $8.00
- AVG Volume (30 Days)
- PTHL 734.8K
- ADAG 36.9K
- Earning Date
- PTHL 02-11-2025
- ADAG 07-24-2025
- Dividend Yield
- PTHL N/A
- ADAG N/A
- EPS Growth
- PTHL N/A
- ADAG N/A
- EPS
- PTHL N/A
- ADAG N/A
- Revenue
- PTHL $448,196.00
- ADAG $103,204.00
- Revenue This Year
- PTHL N/A
- ADAG $6,488.89
- Revenue Next Year
- PTHL N/A
- ADAG $57.50
- P/E Ratio
- PTHL N/A
- ADAG N/A
- Revenue Growth
- PTHL N/A
- ADAG N/A
- 52 Week Low
- PTHL $1.32
- ADAG $1.33
- 52 Week High
- PTHL $8.89
- ADAG $3.58
- Technical
- Relative Strength Index (RSI)
- PTHL N/A
- ADAG 50.35
- Support Level
- PTHL N/A
- ADAG $1.73
- Resistance Level
- PTHL N/A
- ADAG $2.13
- Average True Range (ATR)
- PTHL 0.00
- ADAG 0.17
- MACD
- PTHL 0.00
- ADAG -0.00
- Stochastic Oscillator
- PTHL 0.00
- ADAG 44.44
About PTHL Pheton Holdings Ltd Class A Ordinary Shares
Pheton Holdings Ltd is a healthcare solutions provider dedicated to developing and commercializing treatment software and devices used for brachytherapy. Its proprietary treatment planning system is a type of radiation therapy used in treating cancer patients by placing radioactive sources inside the patient that kill cancer cells and shrink tumors. Its proprietary treatment planning system, FTTPS, is designed to promote the efficiency, accuracy, and safety of brachytherapy. FTTPS is a user-oriented treatment planning system, or TPS, for treating a wide variety of malignant tumors, which can determine the target volume, prescription dose, and dose limitation to protect OARs and produce a safe, effective, and accurate dose distribution plan for brachytherapy for cancer patients.
About ADAG Adagene Inc.
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline.